Loading…
Evaluation the adjunctive use of combined bevacizumab and mitomycinc to trabeculectomy in management of recurrent pediatric glaucoma
Purpose To evaluate the efficacy and safety of combined bevacizumab–mitomycin c (MMC) in recurrent cases of pediatric glaucoma. Methods A prospective non-masked controlled study that included bilateral cases of 12 patients (24 eyes) with recurrent (had previous glaucoma surgery before) pediatric gla...
Saved in:
| Published in: | Eye (London) 2016-01, Vol.30 (1), p.53-58 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c450t-f9cbf5d21794ead57f485bf19e92811bd86a3c8f4556c0038b7b9836cd31196e3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c450t-f9cbf5d21794ead57f485bf19e92811bd86a3c8f4556c0038b7b9836cd31196e3 |
| container_end_page | 58 |
| container_issue | 1 |
| container_start_page | 53 |
| container_title | Eye (London) |
| container_volume | 30 |
| creator | Mahdy, R A Al-Mosallamy, S M Al-Aswad, M A Bor'i, A El-Haig, W M |
| description | Purpose
To evaluate the efficacy and safety of combined bevacizumab–mitomycin c (MMC) in recurrent cases of pediatric glaucoma.
Methods
A prospective non-masked controlled study that included bilateral cases of 12 patients (24 eyes) with recurrent (had previous glaucoma surgery before) pediatric glaucoma. One eye in each patient (12 eyes) was assigned to trabeculectomy operation with combined application of MMC (0.4 mg/ml for 3 min) under and around the scleral flap before trabeculectomy and bevacizumab (avastin) (2.5 mg in 0.2 ml) injected subconjunctivally around the bleb after completing the surgery (group I). The other eye of each patient (12 eyes) was assigned to trabeculectomy operation with application of MMC (0.4 mg/ml for 3 min) only (group II). The mean follow-up period was 13±1 months.
Results
The mean age was 2.16±1.5 (range 7 months to 4.1 years). No significant difference in preoperative intraoperative pressure (IOP) was observed between the groups (
P
>0.05). Recurrent primary congenital glaucoma represents 66.7% of the cases. Other cases included were recurrent aphakic and pseudophakic glaucoma 25% and recurrent post uveitic glaucoma 8.3%. The mean IOP was 12.1±4.2, 12.6±5.4, and 12.8±5.2 mm Hg in group I at 3, 6, and 12 months, respectively, and was 12.8±5.3, 13.7±6.7 and 15.6±5.9 mm Hg in group II at 3, 6, and 12 months, respectively. There was a statistically significant difference in the mean IOP between the studied groups at the 1-year follow-up visit (
P |
| doi_str_mv | 10.1038/eye.2015.182 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4709529</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1760869039</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-f9cbf5d21794ead57f485bf19e92811bd86a3c8f4556c0038b7b9836cd31196e3</originalsourceid><addsrcrecordid>eNptkc1rFDEYxoMotlZvniXgxYOzJplkMrkIpdQPKHhR8BaSzDvbLDPJmkwW1rN_uBm2liqewpvnx_N-PAi9pGRDSdu_gyNsGKFiQ3v2CJ1TLrtGcMEfo3OiBGkYY9_P0LOcd4RUUZKn6Ix1nEnVy3P06_pgpmIWHwNebgGbYVeCW_wBcMmA44hdnK0PMGALB-P8zzIbi00Y8OyXOB-dDw4vES_JWHBlArf-Yh_wbILZwgxhWW1SFVNaiz0M3izJO7ydTKn25jl6Mpopw4u79wJ9-3D99epTc_Pl4-ery5vGcUGWZlTOjmJgVCoOZhBy5L2wI1WgWE-pHfrOtK4fuRCdI_U2VlrVt50bWkpVB-0Fen_y3Rc7w-DqNMlMep_8bNJRR-P130rwt3obD5rLekqmqsGbO4MUfxTIi559djBNJkAsWVPZkb5TpF3R1_-gu1hSqOtVSnDSEknbSr09US7FnBOM98NQotd4dY1Xr_HqGm_FXz1c4B7-k2cFmhOQqxS2kB50_Z_hbxz6s2E</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1754030713</pqid></control><display><type>article</type><title>Evaluation the adjunctive use of combined bevacizumab and mitomycinc to trabeculectomy in management of recurrent pediatric glaucoma</title><source>Open Access: PubMed Central</source><creator>Mahdy, R A ; Al-Mosallamy, S M ; Al-Aswad, M A ; Bor'i, A ; El-Haig, W M</creator><creatorcontrib>Mahdy, R A ; Al-Mosallamy, S M ; Al-Aswad, M A ; Bor'i, A ; El-Haig, W M</creatorcontrib><description>Purpose
To evaluate the efficacy and safety of combined bevacizumab–mitomycin c (MMC) in recurrent cases of pediatric glaucoma.
Methods
A prospective non-masked controlled study that included bilateral cases of 12 patients (24 eyes) with recurrent (had previous glaucoma surgery before) pediatric glaucoma. One eye in each patient (12 eyes) was assigned to trabeculectomy operation with combined application of MMC (0.4 mg/ml for 3 min) under and around the scleral flap before trabeculectomy and bevacizumab (avastin) (2.5 mg in 0.2 ml) injected subconjunctivally around the bleb after completing the surgery (group I). The other eye of each patient (12 eyes) was assigned to trabeculectomy operation with application of MMC (0.4 mg/ml for 3 min) only (group II). The mean follow-up period was 13±1 months.
Results
The mean age was 2.16±1.5 (range 7 months to 4.1 years). No significant difference in preoperative intraoperative pressure (IOP) was observed between the groups (
P
>0.05). Recurrent primary congenital glaucoma represents 66.7% of the cases. Other cases included were recurrent aphakic and pseudophakic glaucoma 25% and recurrent post uveitic glaucoma 8.3%. The mean IOP was 12.1±4.2, 12.6±5.4, and 12.8±5.2 mm Hg in group I at 3, 6, and 12 months, respectively, and was 12.8±5.3, 13.7±6.7 and 15.6±5.9 mm Hg in group II at 3, 6, and 12 months, respectively. There was a statistically significant difference in the mean IOP between the studied groups at the 1-year follow-up visit (
P
<0.05). In addition, group I showed a higher statistically significant difference in absolute and total success (75 and 91.7%, respectively) compared with group II (58.3 and 75%, respectively) (
P
<0.05). The encountered complications included mild hyphema, which occurred in 8.33% in group 1, wound leakage, which occurred in 8.33% in each group, and shallow anterior chamber (AC), which occurred in 16.7% in each group and was the most common encountered complication in the study. One case of shallow AC in group I led to choroidal effusion (8.33%). One case in group II developed late bleb-related endophthalmitis after 3 months, which resulted in phthisis bulbi (8.33%).
Conclusion
The additive effect of subconjunctival bevacizumab to MMC-augmented trabeculectomy in the case of recurrent pediatric glaucoma was beneficial in improving the success rate. Better IOP control and prolonging the bleb survivalvia reducing the long-term need of using anti-glaucoma drugs postoperatively without adding complications had also been achieved with this technique. This offers a promising alternative for the treatment of this type of glaucoma.</description><identifier>ISSN: 0950-222X</identifier><identifier>EISSN: 1476-5454</identifier><identifier>DOI: 10.1038/eye.2015.182</identifier><identifier>PMID: 26427987</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/1807 ; 692/699/3161 ; Alkylating Agents - administration & dosage ; Angiogenesis Inhibitors - therapeutic use ; Bevacizumab - therapeutic use ; Child, Preschool ; Clinical Study ; Drug Therapy, Combination ; Follow-Up Studies ; Glaucoma ; Humans ; Hydrophthalmos - drug therapy ; Hydrophthalmos - physiopathology ; Hydrophthalmos - surgery ; Hydrophthalmos - therapy ; Infant ; Injections, Intraocular ; Intraocular Pressure - physiology ; Laboratory Medicine ; Medicine ; Medicine & Public Health ; Mitomycin - administration & dosage ; Ophthalmology ; Pharmaceutical Sciences/Technology ; Prospective Studies ; Recurrence ; Surgery ; Surgical Oncology ; Trabeculectomy ; Treatment Outcome ; Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><ispartof>Eye (London), 2016-01, Vol.30 (1), p.53-58</ispartof><rights>Royal College of Ophthalmologists 2016</rights><rights>Copyright Nature Publishing Group Jan 2016</rights><rights>Copyright © 2016 Royal College of Ophthalmologists 2016 Royal College of Ophthalmologists</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-f9cbf5d21794ead57f485bf19e92811bd86a3c8f4556c0038b7b9836cd31196e3</citedby><cites>FETCH-LOGICAL-c450t-f9cbf5d21794ead57f485bf19e92811bd86a3c8f4556c0038b7b9836cd31196e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709529/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709529/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26427987$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mahdy, R A</creatorcontrib><creatorcontrib>Al-Mosallamy, S M</creatorcontrib><creatorcontrib>Al-Aswad, M A</creatorcontrib><creatorcontrib>Bor'i, A</creatorcontrib><creatorcontrib>El-Haig, W M</creatorcontrib><title>Evaluation the adjunctive use of combined bevacizumab and mitomycinc to trabeculectomy in management of recurrent pediatric glaucoma</title><title>Eye (London)</title><addtitle>Eye</addtitle><addtitle>Eye (Lond)</addtitle><description>Purpose
To evaluate the efficacy and safety of combined bevacizumab–mitomycin c (MMC) in recurrent cases of pediatric glaucoma.
Methods
A prospective non-masked controlled study that included bilateral cases of 12 patients (24 eyes) with recurrent (had previous glaucoma surgery before) pediatric glaucoma. One eye in each patient (12 eyes) was assigned to trabeculectomy operation with combined application of MMC (0.4 mg/ml for 3 min) under and around the scleral flap before trabeculectomy and bevacizumab (avastin) (2.5 mg in 0.2 ml) injected subconjunctivally around the bleb after completing the surgery (group I). The other eye of each patient (12 eyes) was assigned to trabeculectomy operation with application of MMC (0.4 mg/ml for 3 min) only (group II). The mean follow-up period was 13±1 months.
Results
The mean age was 2.16±1.5 (range 7 months to 4.1 years). No significant difference in preoperative intraoperative pressure (IOP) was observed between the groups (
P
>0.05). Recurrent primary congenital glaucoma represents 66.7% of the cases. Other cases included were recurrent aphakic and pseudophakic glaucoma 25% and recurrent post uveitic glaucoma 8.3%. The mean IOP was 12.1±4.2, 12.6±5.4, and 12.8±5.2 mm Hg in group I at 3, 6, and 12 months, respectively, and was 12.8±5.3, 13.7±6.7 and 15.6±5.9 mm Hg in group II at 3, 6, and 12 months, respectively. There was a statistically significant difference in the mean IOP between the studied groups at the 1-year follow-up visit (
P
<0.05). In addition, group I showed a higher statistically significant difference in absolute and total success (75 and 91.7%, respectively) compared with group II (58.3 and 75%, respectively) (
P
<0.05). The encountered complications included mild hyphema, which occurred in 8.33% in group 1, wound leakage, which occurred in 8.33% in each group, and shallow anterior chamber (AC), which occurred in 16.7% in each group and was the most common encountered complication in the study. One case of shallow AC in group I led to choroidal effusion (8.33%). One case in group II developed late bleb-related endophthalmitis after 3 months, which resulted in phthisis bulbi (8.33%).
Conclusion
The additive effect of subconjunctival bevacizumab to MMC-augmented trabeculectomy in the case of recurrent pediatric glaucoma was beneficial in improving the success rate. Better IOP control and prolonging the bleb survivalvia reducing the long-term need of using anti-glaucoma drugs postoperatively without adding complications had also been achieved with this technique. This offers a promising alternative for the treatment of this type of glaucoma.</description><subject>692/1807</subject><subject>692/699/3161</subject><subject>Alkylating Agents - administration & dosage</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Bevacizumab - therapeutic use</subject><subject>Child, Preschool</subject><subject>Clinical Study</subject><subject>Drug Therapy, Combination</subject><subject>Follow-Up Studies</subject><subject>Glaucoma</subject><subject>Humans</subject><subject>Hydrophthalmos - drug therapy</subject><subject>Hydrophthalmos - physiopathology</subject><subject>Hydrophthalmos - surgery</subject><subject>Hydrophthalmos - therapy</subject><subject>Infant</subject><subject>Injections, Intraocular</subject><subject>Intraocular Pressure - physiology</subject><subject>Laboratory Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mitomycin - administration & dosage</subject><subject>Ophthalmology</subject><subject>Pharmaceutical Sciences/Technology</subject><subject>Prospective Studies</subject><subject>Recurrence</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Trabeculectomy</subject><subject>Treatment Outcome</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><issn>0950-222X</issn><issn>1476-5454</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNptkc1rFDEYxoMotlZvniXgxYOzJplkMrkIpdQPKHhR8BaSzDvbLDPJmkwW1rN_uBm2liqewpvnx_N-PAi9pGRDSdu_gyNsGKFiQ3v2CJ1TLrtGcMEfo3OiBGkYY9_P0LOcd4RUUZKn6Ix1nEnVy3P06_pgpmIWHwNebgGbYVeCW_wBcMmA44hdnK0PMGALB-P8zzIbi00Y8OyXOB-dDw4vES_JWHBlArf-Yh_wbILZwgxhWW1SFVNaiz0M3izJO7ydTKn25jl6Mpopw4u79wJ9-3D99epTc_Pl4-ery5vGcUGWZlTOjmJgVCoOZhBy5L2wI1WgWE-pHfrOtK4fuRCdI_U2VlrVt50bWkpVB-0Fen_y3Rc7w-DqNMlMep_8bNJRR-P130rwt3obD5rLekqmqsGbO4MUfxTIi559djBNJkAsWVPZkb5TpF3R1_-gu1hSqOtVSnDSEknbSr09US7FnBOM98NQotd4dY1Xr_HqGm_FXz1c4B7-k2cFmhOQqxS2kB50_Z_hbxz6s2E</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Mahdy, R A</creator><creator>Al-Mosallamy, S M</creator><creator>Al-Aswad, M A</creator><creator>Bor'i, A</creator><creator>El-Haig, W M</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160101</creationdate><title>Evaluation the adjunctive use of combined bevacizumab and mitomycinc to trabeculectomy in management of recurrent pediatric glaucoma</title><author>Mahdy, R A ; Al-Mosallamy, S M ; Al-Aswad, M A ; Bor'i, A ; El-Haig, W M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-f9cbf5d21794ead57f485bf19e92811bd86a3c8f4556c0038b7b9836cd31196e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>692/1807</topic><topic>692/699/3161</topic><topic>Alkylating Agents - administration & dosage</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Bevacizumab - therapeutic use</topic><topic>Child, Preschool</topic><topic>Clinical Study</topic><topic>Drug Therapy, Combination</topic><topic>Follow-Up Studies</topic><topic>Glaucoma</topic><topic>Humans</topic><topic>Hydrophthalmos - drug therapy</topic><topic>Hydrophthalmos - physiopathology</topic><topic>Hydrophthalmos - surgery</topic><topic>Hydrophthalmos - therapy</topic><topic>Infant</topic><topic>Injections, Intraocular</topic><topic>Intraocular Pressure - physiology</topic><topic>Laboratory Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mitomycin - administration & dosage</topic><topic>Ophthalmology</topic><topic>Pharmaceutical Sciences/Technology</topic><topic>Prospective Studies</topic><topic>Recurrence</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Trabeculectomy</topic><topic>Treatment Outcome</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mahdy, R A</creatorcontrib><creatorcontrib>Al-Mosallamy, S M</creatorcontrib><creatorcontrib>Al-Aswad, M A</creatorcontrib><creatorcontrib>Bor'i, A</creatorcontrib><creatorcontrib>El-Haig, W M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Eye (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mahdy, R A</au><au>Al-Mosallamy, S M</au><au>Al-Aswad, M A</au><au>Bor'i, A</au><au>El-Haig, W M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation the adjunctive use of combined bevacizumab and mitomycinc to trabeculectomy in management of recurrent pediatric glaucoma</atitle><jtitle>Eye (London)</jtitle><stitle>Eye</stitle><addtitle>Eye (Lond)</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>30</volume><issue>1</issue><spage>53</spage><epage>58</epage><pages>53-58</pages><issn>0950-222X</issn><eissn>1476-5454</eissn><abstract>Purpose
To evaluate the efficacy and safety of combined bevacizumab–mitomycin c (MMC) in recurrent cases of pediatric glaucoma.
Methods
A prospective non-masked controlled study that included bilateral cases of 12 patients (24 eyes) with recurrent (had previous glaucoma surgery before) pediatric glaucoma. One eye in each patient (12 eyes) was assigned to trabeculectomy operation with combined application of MMC (0.4 mg/ml for 3 min) under and around the scleral flap before trabeculectomy and bevacizumab (avastin) (2.5 mg in 0.2 ml) injected subconjunctivally around the bleb after completing the surgery (group I). The other eye of each patient (12 eyes) was assigned to trabeculectomy operation with application of MMC (0.4 mg/ml for 3 min) only (group II). The mean follow-up period was 13±1 months.
Results
The mean age was 2.16±1.5 (range 7 months to 4.1 years). No significant difference in preoperative intraoperative pressure (IOP) was observed between the groups (
P
>0.05). Recurrent primary congenital glaucoma represents 66.7% of the cases. Other cases included were recurrent aphakic and pseudophakic glaucoma 25% and recurrent post uveitic glaucoma 8.3%. The mean IOP was 12.1±4.2, 12.6±5.4, and 12.8±5.2 mm Hg in group I at 3, 6, and 12 months, respectively, and was 12.8±5.3, 13.7±6.7 and 15.6±5.9 mm Hg in group II at 3, 6, and 12 months, respectively. There was a statistically significant difference in the mean IOP between the studied groups at the 1-year follow-up visit (
P
<0.05). In addition, group I showed a higher statistically significant difference in absolute and total success (75 and 91.7%, respectively) compared with group II (58.3 and 75%, respectively) (
P
<0.05). The encountered complications included mild hyphema, which occurred in 8.33% in group 1, wound leakage, which occurred in 8.33% in each group, and shallow anterior chamber (AC), which occurred in 16.7% in each group and was the most common encountered complication in the study. One case of shallow AC in group I led to choroidal effusion (8.33%). One case in group II developed late bleb-related endophthalmitis after 3 months, which resulted in phthisis bulbi (8.33%).
Conclusion
The additive effect of subconjunctival bevacizumab to MMC-augmented trabeculectomy in the case of recurrent pediatric glaucoma was beneficial in improving the success rate. Better IOP control and prolonging the bleb survivalvia reducing the long-term need of using anti-glaucoma drugs postoperatively without adding complications had also been achieved with this technique. This offers a promising alternative for the treatment of this type of glaucoma.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>26427987</pmid><doi>10.1038/eye.2015.182</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0950-222X |
| ispartof | Eye (London), 2016-01, Vol.30 (1), p.53-58 |
| issn | 0950-222X 1476-5454 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4709529 |
| source | Open Access: PubMed Central |
| subjects | 692/1807 692/699/3161 Alkylating Agents - administration & dosage Angiogenesis Inhibitors - therapeutic use Bevacizumab - therapeutic use Child, Preschool Clinical Study Drug Therapy, Combination Follow-Up Studies Glaucoma Humans Hydrophthalmos - drug therapy Hydrophthalmos - physiopathology Hydrophthalmos - surgery Hydrophthalmos - therapy Infant Injections, Intraocular Intraocular Pressure - physiology Laboratory Medicine Medicine Medicine & Public Health Mitomycin - administration & dosage Ophthalmology Pharmaceutical Sciences/Technology Prospective Studies Recurrence Surgery Surgical Oncology Trabeculectomy Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors |
| title | Evaluation the adjunctive use of combined bevacizumab and mitomycinc to trabeculectomy in management of recurrent pediatric glaucoma |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T16%3A48%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20the%20adjunctive%20use%20of%20combined%20bevacizumab%20and%20mitomycinc%20to%20trabeculectomy%20in%20management%20of%20recurrent%20pediatric%20glaucoma&rft.jtitle=Eye%20(London)&rft.au=Mahdy,%20R%20A&rft.date=2016-01-01&rft.volume=30&rft.issue=1&rft.spage=53&rft.epage=58&rft.pages=53-58&rft.issn=0950-222X&rft.eissn=1476-5454&rft_id=info:doi/10.1038/eye.2015.182&rft_dat=%3Cproquest_pubme%3E1760869039%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c450t-f9cbf5d21794ead57f485bf19e92811bd86a3c8f4556c0038b7b9836cd31196e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1754030713&rft_id=info:pmid/26427987&rfr_iscdi=true |